Pressmeddelanden, rapporter och bolagsmeddelande för PILA PHARMA AB

PILA PHARMA AB, a Swedish biotech company, announced that the last day for trading in paid subscribed units related to its rights issue is expected to be on August 5, 2025. The new shares are anticipated to begin trading on Nasdaq First North Growth Market on August 11, 2025. PILA PHARMA focuses on developing TRPV1 antagonists, including XEN-D0501, for treating obesity and type 2 diabetes. The company has completed two phase 2a clinical trials indicating the compound's safety and efficacy. Future plans include further clinical trials and potential treatments for erythromelalgia and abdominal aorta aneurism. The company is involved in a research collaboration with Uppsala University and has received orphan drug designation for XEN-D0501. Legal restrictions apply to the distribution of this press release in certain jurisdictions, and it does not constitute an offer for securities. The announcement includes forward-looking statements subject to risks and uncertainties.

PILA PHARMA AB has completed a rights issue of units, with a directed issue of 487,500 units to underwriters as compensation, priced at SEK 2.00 per unit. This aims to fulfill contractual obligations and improve the company's financial position. The Compensation Issue will increase the number of shares by 487,500 and the share capital by SEK 20,843.617032, resulting in a 1.2% dilution effect. If all warrants are exercised, the number of shares will further increase by 975,000, leading to a 1.4% total dilution effect. The warrants allow subscription for new shares between February 5-15, 2026, at a price between SEK 1.50 and SEK 3.00 per share. PILA PHARMA is a Swedish biotech company focused on developing treatments for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurism, with its candidate XEN-D0501 showing promising results. The press release includes legal restrictions on its distribution and emphasizes the forward-looking nature of the statements.

PILA PHARMA AB announced the final results of its rights issue involving up to 9,994,019 units, each comprising one share and one warrant of series TO2. The rights issue was oversubscribed, with 7,890,774 units subscribed via unit rights and applications for 21,441,385 units without unit rights, totaling approximately 293.49% of the issue. This will provide the company with approximately SEK 20 million before costs, with potential for an additional SEK 60 million upon full exercise of the warrants. Due to oversubscription, the company will conduct an over-allotment issue of up to 4,476,273 units, potentially raising an additional SEK 8.95 million, and up to SEK 26.85 million upon full exercise of the warrants. The rights issue will increase the number of shares from 27,126,623 to 37,120,642, with further increases possible upon warrant exercise. The last trading day for the paid subscribed units is expected to be August 6, 2025, with new shares trading on Nasdaq First North Growth Market from August 12, 2025. PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating obesity and type 2 diabetes, with its development candidate XEN-D0501. The company has completed two phase 2a clinical trials and is preparing for the next trial, PP-CT03, to evaluate the safety and efficacy of XEN-D0501.

PILA PHARMA AB is conducting a rights issue of units, with the last day for subscription being 15 July 2025, although some banks have set an earlier deadline of 14 July. The rights issue involves a maximum of 9,994,019 units, with each unit comprising one newly issued share and one warrant of series TO2. The subscription price is SEK 2.00 per unit, and the warrants allow for the subscription of additional shares between 5 February 2026 and 15 February 2026 at a price based on the market average, with a minimum of SEK 1.50 and a maximum of SEK 3.00 per share. The issue is nearly fully covered by commitments from shareholders and guarantees. If oversubscribed, an additional allotment may be issued. The company is a Swedish biotech firm focusing on TRPV1 antagonists for treating obesity and type 2 diabetes. Their development candidate, XEN-D0501, has shown promise in clinical trials, and they are preparing for further studies. The press release includes legal disclaimers and forward-looking statements, emphasizing that the information provided is not exhaustive and should not be relied upon for investment decisions.

On July 10, 2025, PILA PHARMA AB concludes trading in unit rights related to its rights issue, resolved on June 19, 2025. The rights issue involves up to 9,994,019 units, with 19 unit rights allowing subscription for seven units, each priced at SEK 2.00. Each unit includes one new share and a warrant, enabling subscription for two new shares between February 5-15, 2026, at a price based on market averages, but not less than SEK 1.50 or more than SEK 3.00. The subscription period runs from July 1-15, 2025, with existing shareholders and management committing SEK 10.22 million, covering 51.12% of the issue, and additional guarantees of SEK 9.75 million, totaling 99.87% coverage. An over-allotment option of up to 4,963,773 units may be exercised if oversubscribed. PILA PHARMA, a Swedish biotech firm, focuses on developing TRPV1 antagonists for treating obesity and type 2 diabetes, with ongoing clinical trials and research collaborations. The company also explores applications for erythromelalgia and abdominal aorta aneurism. The press release includes disclaimers about distribution restrictions and forward-looking statements.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition to treat obesity and diabetes. The company participated in a podcast to discuss its proprietary TRPV1 inhibitor's potential in obesity studies and its ongoing rights issue, which is nearly fully covered by existing investors. The funds raised will support obesity studies aimed at creating a comprehensive data package for potential partnerships. PILA PHARMA focuses on developing drugs for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. The company has conducted successful phase 2a trials with its TRPV1 antagonist, XEN-D0501, showing good tolerability and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. PILA PHARMA plans to progress into longer clinical trials and is preparing for a new trial to evaluate XEN-D0501's safety and efficacy in obesity and diabetes. The company also explores treatments for erythromelalgia and abdominal aorta aneurysm, with ongoing research collaborations and plans for proof-of-concept studies.

PILA PHARMA AB, a Swedish biotech company, is developing new oral drugs targeting TRPV1 inhibition for obesity and diabetes treatment. The company is conducting a rights issue to fund a new venture focused on obesity studies, supported by existing investors and guarantor commitments. CEO Gustav H. Gram discusses the company's scientific approach and the rights issue in an interview with Finwire. PILA PHARMA aims to generate comprehensive data to facilitate partnerships. The company is also involved in projects related to type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. Their drug XEN-D0501 has shown promise in clinical trials for obesity and diabetes and has potential applications in other inflammatory and metabolic disorders. The company is preparing for further clinical trials to assess the safety and efficacy of XEN-D0501. Additionally, PILA PHARMA is exploring treatments for erythromelalgia and abdominal aorta aneurysm, with plans for clinical trials and potential out-licensing opportunities.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. The company is conducting a rights issue to fund a new venture focused on obesity studies, which is supported by existing investors and pre-commitments. CEO Gustav H. Gram discussed this initiative in an interview with Mathias Vahlne from Direkt Studios. PILA PHARMA aims to develop a comprehensive data package to facilitate partnerships. The company owns a TRPV1 asset, including the development candidate XEN-D0501, and holds patents for using TRPV1 antagonists in treating obesity and diabetes. XEN-D0501 has shown promising results in clinical trials, demonstrating good tolerability and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. The company is preparing for further clinical trials to evaluate the safety and efficacy of XEN-D0501. In addition to obesity and diabetes, PILA PHARMA is working on projects related to erythromelalgia and abdominal aorta aneurysm. The company collaborates with Uppsala University and has demonstrated preclinical proof-of-concept for using XEN-D0501 in reducing abdominal aorta aneurysm growth. PILA PHARMA's shares are traded on Nasdaq First North Growth Market in Sweden.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs using TRPV1 inhibition to treat obesity and diabetes. The company announced its participation in a new podcast episode with Joakim Båge from the 10X podcast, where CEO Gustav H. Gram discussed the company's plans to explore their TRPV1 inhibitor in obesity studies. They also talked about an ongoing rights issue, largely supported by existing investors, to fund these studies. PILA PHARMA aims to create a comprehensive data package to facilitate partnerships and continues to focus on developing drugs for obesity and diabetes. The company owns a TRPV1 asset, XEN-D0501, which has shown promise in clinical trials for treating obesity and diabetes. PILA PHARMA is also exploring treatments for erythromelalgia and abdominal aorta aneurysm, with ongoing research and development efforts in these areas.

PILA PHARMA AB has initiated a rights issue of units to raise approximately 20 million SEK, with the subscription period running from July 1 to July 15, 2025. Existing shareholders have preferential rights, and the issue includes a maximum of 9,994,019 units, each comprising one newly issued share and one warrant. The subscription price is SEK 2.00 per unit. The warrants allow holders to subscribe for additional shares between February 5 and February 15, 2026, at a price determined by the average market price, with certain limits. The company has secured commitments covering nearly the entire rights issue amount. An over-allotment issue may occur if the rights issue is oversubscribed. PILA PHARMA focuses on developing treatments for obesity, type 2 diabetes, and erythromelalgia using TRPV1 antagonists, specifically the compound XEN-D0501. The company is preparing for further clinical trials to assess safety and efficacy in treating these conditions. The press release includes legal disclaimers about distribution restrictions and forward-looking statements.